REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 218 filers reported holding REATA PHARMACEUTICALS INC in Q1 2020. The put-call ratio across all filers is 0.42 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $281,000 | -11.9% | 8,565 | -29.1% | 0.02% | -15.0% |
| Q4 2021 | $319,000 | -94.7% | 12,085 | -79.8% | 0.02% | -95.0% |
| Q3 2021 | $6,014,000 | +23.7% | 59,775 | +74.0% | 0.40% | +26.4% |
| Q2 2021 | $4,862,000 | +89.0% | 34,355 | +33.1% | 0.31% | +65.3% |
| Q1 2021 | $2,573,000 | -16.1% | 25,805 | +4.1% | 0.19% | -21.2% |
| Q4 2020 | $3,065,000 | +43.2% | 24,790 | +12.8% | 0.24% | +25.5% |
| Q3 2020 | $2,141,000 | -29.6% | 21,980 | +12.7% | 0.19% | -30.2% |
| Q2 2020 | $3,042,000 | +161.8% | 19,500 | +142.2% | 0.28% | +133.1% |
| Q1 2020 | $1,162,000 | -24.2% | 8,050 | +7.3% | 0.12% | +51.3% |
| Q4 2019 | $1,533,000 | +154.7% | 7,500 | 0.0% | 0.08% | +200.0% |
| Q3 2019 | $602,000 | -15.0% | 7,500 | 0.0% | 0.03% | -7.1% |
| Q2 2019 | $708,000 | +29.4% | 7,500 | +17.2% | 0.03% | +33.3% |
| Q1 2019 | $547,000 | +62.3% | 6,400 | +6.7% | 0.02% | +40.0% |
| Q4 2018 | $337,000 | – | 6,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Conrad N. Hilton Foundation | 63,481 | $7,847,000 | 100.00% |
| CPMG Inc | 2,896,901 | $358,115,000 | 55.16% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 140,000 | $17,307,000 | 26.62% |
| Corriente Advisors, LLC | 525,000 | $64,901,000 | 15.45% |
| DUMAC, INC. | 76,050 | $9,401,000 | 7.33% |
| MADDEN SECURITIES Corp | 35,152 | $4,345,000 | 2.80% |
| Biondo Investment Advisors, LLC | 113,692 | $14,055,000 | 2.69% |
| Duquesne Family Office | 749,897 | $92,702,000 | 2.50% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $3,754,000 | 2.44% |
| Integral Health Asset Management, LLC | 50,000 | $6,181,000 | 1.84% |